In in vitro studies, concomitant TIGIT and PD-1 blockade additively increased proliferation, cytokines production and degranulation of both tumor antigen-specific CD8+ T cells and CD8+ TILs from advanced melanoma patients [68]. Here, PDCD1 is linked to melanoma.